MOTS-c
Mitochondrial / metabolic
Status & caution. Not FDA-approved. Among the 12 peptides removed from Category 2 in April 2026 and scheduled for PCAC review on 23 July 2026. Exciting metabolic biology but early-stage; human evidence is minimal.
At a glance
Indications & what it's studied for
Studied for insulin sensitivity, metabolic regulation, exercise capacity, and aging; influences AMPK signalling and nuclear gene expression.
Contraindications & cautions
No established human contraindications; no approved use.
Commonly reported dosing
Reported, not recommended. The following describes what appears in research literature and community use. It is not a protocol, and unapproved peptides have no validated human dosing.
Community protocols report intermittent subcutaneous dosing; unvalidated.
Routes of administration
Subcutaneous injection.
Don't combine with
No characterised interactions; effects on glucose handling warrant care alongside glucose-lowering drugs.
Reported to stack with
Sometimes grouped with other 'longevity' peptides (e.g. epitalon); no validated combinations.
Note: "stacking" combines multiple agents and multiplies unknowns; popularity of a combination is not evidence of its safety.
What the research actually shows
Notable rodent metabolic studies and early mechanistic human-cell work; clinical trials are at an early stage.
Before acting on anything here, see Safety & the grey market and how to read a COA.